重庆市2004-2013年艾滋病抗病毒治疗患者生存时间及影响因素分析

何海; 李巧巧; 周超; 曾璨; 崔鑫宇; 吴国辉; 栾荣生

doi:10.16462/j.cnki.zhjbkz.2016.01.006

重庆市2004-2013年艾滋病抗病毒治疗患者生存时间及影响因素分析

doi: 10.16462/j.cnki.zhjbkz.2016.01.006

1. 四川大学华西公共卫生学院流行病与卫生统计学系, 四川成都 610041;
2. 重庆市疾病预防控制中心性病艾滋病防治所, 重庆 400042

基金项目:

中国-默沙东艾滋病合作项目Ⅱ期（A42001）

详细信息

作者简介:
何海(1990-),男,四川安岳人,在读硕士研究生。主要研究方向：行为流行病学。

中图分类号: R512.91;R181
计量
- 文章访问数: 342
- HTML全文浏览量: 83
- PDF下载量: 65
- 被引次数: 0
出版历程
- 收稿日期: 2015-10-17
- 修回日期: 2015-11-20

Survival and influencing factors analysis on AIDS antiretroviral therapy in Chongqing during 2004-2013

1. Department of Epidemiology and Health Statistics, School of West China School of Public Health of Sichuan University, Chengdu 610041, China;
2. Department for STD and AIDS Prevention and Control, Chongqing Provincial Center for Disease Control and Provention, Chongqing 400042, China

摘要

摘要: 目的了解重庆市接受艾滋病高效抗病毒治疗的患者的生存状况及影响因素。方法利用国家艾滋病抗病毒治疗信息系统，收集患者的生存、死亡信息，采用 SPSS 17.0 进行数据分析。结果共收集到8 991例于重庆市接受艾滋病抗病毒治疗的患者的流行病学信息，因艾滋病相关疾病死亡592例，艾滋病患者总病死率5.40/1 000人月，患者1～5年累计生存率分别为0.92、0.90、0.89、0.87、0.84。多因素Cox回归提示相对于入组年龄<30岁组，30～岁组、40～岁组、≥50岁组HR（95% CI）分别为1.424（1.025～1.978）、1.881（1.362～2.597）、2.853（2.072～3.927）;相对于基线CD4⁺T淋巴细胞计数≥200 个/mm³组，CD4⁺T淋巴细胞计数<100 个/mm³组与100～个/mm³组HR（95% CI）分别为4.847（3.792～6.196）、1.962（1.486～2.590）;感染途径为静脉吸毒（HR=1.964，95% CI：1.544～2.498）、入组时艾滋病相关疾病或症状（HR=2.658，95% CI：2.221～3.181）也是艾滋病相关疾病死亡的危险因素。结论重庆市艾滋病抗病毒治疗有效地减少了艾滋病相关疾病死亡，延长了患者生存时间;降低治疗门槛，及时纳入患者进行抗病毒治疗对提高艾滋病抗病毒治疗效果有重要意义。
- 获得性免疫缺陷综合征 /
- 抗病毒药 /
- 流行病学研究
Abstract: Objective To study the effect and the influencing factors of the highly active antiretroviral therapy(HAART) in Chongqing. Methods Data on the survival and death of AIDS patients were collected from the National HAART reporting system between 2004 and 2013, and analyzed using SPSS 17.0 software. Results 8 991 cases were enrolled in this study, 592 died of AIDS. Total AIDS mortality was 5.40/1 000 person-months. The cumulative survival rate of antiretroviral therapy after 1-5 years were 0.92,0.90,0.89,0.87,0.84 respectively. Data from Cox proportional hazard regression model analysis indicated that after adjustment for other influencing factors, the risk of death increased with the growing age and lower baseline CD4⁺T cells counts. The HR(95% CI) of 30-39 years、40-49 yrears and≥50 years group were 1.424(1.025-1.978),1.881(1.362-2.597),2.853(2.072-3.927) relative to<30 years group, respectively. The HR(95% CI) of 100-199/mm³ and<100/mm³ baseline CD4⁺T cells counts group were 1.962(1.486-2.590),4.847(3.792-6.196) relative to≥200/mm³ group.The intravenous drug users(HR=1.964,95% CI：1.544-2.498), opportunistic infection or manifestation(HR=2.658,95% CI：2.221-3.181) were also the risk factors of death.Conclusions The HARRT had significantly reduced the mortality rate. To improve the effect of HARRT in Chongqing, more effective measures should to be taken to make the AIDS patients enrolled HAART earlier.
- Acquired immunodeficiency syndrome /
- Antiviral agents /
- Epidemiologic studies

HTML全文

参考文献(10)

Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China national free antiretroviral treatment program [J]. AnnIntern Med, 2009,151(4):241-251.

Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:comparison between low-come and high-income countries [J]. Lancet, 2006,367(9513):817-824.

张福杰. 国家免费艾滋病抗病毒治疗手册 [M]. 第3版. 北京:人民卫生出社, 2012:15-18.

彭国平,李旺华,占发先,等. 湖北省2715例接受艾滋病免费抗病毒治疗者生存分析 [J]. 公共卫生与预防医学, 2011,22(5):33-36.

姚世堂,段松,项丽芬,等. 云南省德宏州3103例艾滋病患者抗病毒治疗后生存分析 [J]. 中华流行病学杂志, 2010,11(31):1215-1218.

Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy [J]. Ann Intern Med, 2000,133(6):401-410.

Cuong do D, Thorson A, Sonnerborg A, et al. Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam [J]. Scand J Infect Dis, 2012,44(3):201-208.

杨红,陈果,周良君,等. 绵阳市228例艾滋病感染者和病人CD4⁺T淋巴细胞检测分析 [J]. 中国热带医学, 2013,13(3):335-342.

原琛利,穆生财,薛子东. 山西省艾滋病抗病毒治疗死亡病例流行病学分析 [J]. 中华疾病控制杂志, 2014,18(12):1184-1186.

[KG*2]Alencar WK, Duarte PS, Waldman EA, et al. Survival analysis of acquired immune deficiency syndromepatients with and without hepatitis C virus infection at areference center for sexually transmitted diseases/acquiredimmune deficiency syndrome in Sao Paulo,Brazil [J]. Braz J Infect Dis, 2014,18(2):150-157.

施引文献

资源附件(0)

访问统计